Crinetics Pharmaceuticals Inc.
CRNXHeld by 11 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying11 funds opened new positions. Next phase3 readout (Paltusotine): Jul 2023. Short interest: 15.7% of float.
Held by 11 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying11 funds opened new positions. Next phase3 readout (Paltusotine): Jul 2023. Short interest: 15.7% of float.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.